Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521714 | 0.86 | HSD11B1 (0.53) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL4525522 | 0.85 | HSD11B1 (0.56) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL4520088 | 0.84 | HSD11B1 (0.55) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL4520065 | 0.84 | HSD11B1 (0.60) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL3836585 | 0.84 | HSD11B1 (0.55) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL4512987 | 0.83 | HSD11B1 (0.53) | HSD11B1CYP2D6HPGDAVPR1ANPY5R | |
| SCHEMBL4517279 | 0.83 | HSD11B1 (0.53) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL3840207 | 0.83 | NPY5R (0.55) | AVPR1ANPY5R | |
| SCHEMBL4515925 | 0.83 | HSD11B1 (0.50) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL4503697 | 0.81 | HSD11B1 (0.51) | HSD11B1CYP2D6AVPR1ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | claimed |
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | INCYTE CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | disclosed |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | disclosed |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | disclosed |
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885CYP2D6 253/4885HPGD 46/4885 |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885CYP2D6 253/4885HPGD 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.